ARTICLE
4 March 2020

CBD Company Files Motion To Dismiss In Trade Secret Dispute

SS
Seyfarth Shaw LLP

Contributor

With more than 900 lawyers across 18 offices, Seyfarth Shaw LLP provides advisory, litigation, and transactional legal services to clients worldwide. Our high-caliber legal representation and advanced delivery capabilities allow us to take on our clients’ unique challenges and opportunities-no matter the scale or complexity. Whether navigating complex litigation, negotiating transformational deals, or advising on cross-border projects, our attorneys achieve exceptional legal outcomes. Our drive for excellence leads us to seek out better ways to work with our clients and each other. We have been first-to-market on many legal service delivery innovations-and we continue to break new ground with our clients every day. This long history of excellence and innovation has created a culture with a sense of purpose and belonging for all. In turn, our culture drives our commitment to the growth of our clients, the diversity of our people, and the resilience of our workforce.
Medterra was founded in 2017 and sells a host of CBD products aimed at treating a variety of symptoms and issues.
United States Intellectual Property

On February 18, 2020, Medterra CBD filed a motion to dismiss a lawsuit alleging that it had misappropriated Healthcare Resources Management Group LLC's ("Healthcare Resource") proprietary formula for a CBD cream aimed at treating pain. In its motion, Medterra argued that Healthcare Resource failed to allege that it had provided or that Medterra had otherwise acquired any proprietary information. Additionally, Medterra claims that even if Healthcare Resource could establish that it had provided its propriety CBD cream formula to Medterra, Healthcare Resource did not take adequate steps to protect its trade secret by mandating Medterra sign a non-disclosure agreement.

Medterra was founded in 2017 and sells a host of CBD products aimed at treating a variety of symptoms and issues. On its website, Medterra claims that it sells "100% natural, THC free, 99% pure CBD" that is grown in accordance to guidelines set by the Kentucky Department of Agriculture. Medterra contacted Healthcare Resources in March of 2018 in search of a manufacturer for its CBD-based pain cream. Healthcare Resources responded that it was willing to produce its own cream for Medterra on a "white label" basis, thereby allowing Medterra to sell the product under the Medterra brand name. Medterra accepted this offer and Healthcare Resources engaged a third company, EcoNatura All Healthy World, LLC ("EcoNatura"), to manufacture the product.

The parties' relationship began to sour when Medterra and EcoNatura started working directly together, including corresponding about the formulation of a variety of CBD-based products. These discussions culminated in Medterra requesting that EcoNatura stop producing Healthcare Resources' proprietary cream for other companies. Medterra claims that Healthcare Resources was amenable to this exclusivity arrangement subject to the parties agreeing on pricing terms. Healthcare Resources attempted to have both Medterra and EcoNatura sign an NDA, but neither party ever executed one. For its own reasons, eventually, Healthcare Resources selected a new manufacturer to replace EcoNatura and sent new pricing to Medterra. Medterra never responded to these pricing terms. In its suit, Healthcare Resources claims that Medterra is still purchasing its proprietary cream from EcoNatura.

This case serves as an interesting example of how CBD companies, like companies in other nascent industries, can be embroiled in trade secret litigation. It is critical that CBD companies, particularly given the relatively uncertain and evolving regulatory landscape, consult with counsel to ensure that their products are not only compliant with existing regulations, but also that what they are seeking to do does not infringe upon another company's protected intellectual property.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More